文献速递骨软组织肉瘤与黑色素瘤

纳武利尤单抗联合大分割放疗治疗晚期黑色素瘤患者的2期试验

Nivolumab and hypofractionated radiotherapy in patients with advanced melanoma: A phase 2 trial.
PubMed 文献 · Eur J Cancer · 2025-01-22

这项多中心、非随机2期试验入组64例初治转移性黑色素瘤患者,给予纳武利尤单抗(240 mg/2周)联合放疗(第15天,6 Gy×3)。2年OS率和1年PFS率分别为65.2%和56%。联合治疗与历史队列相比未改善生存,放疗方案需优化。

要点

  • 纳武利尤单抗联合大分割放疗的2年OS率为65.2%,1年PFS率为56%。
  • ECOG-PS(1 vs 0;HR=3.5;P=0.005)是OS的独立预后因素。
  • 3-4级治疗相关不良事件发生率为21.9%,无5级事件。

核心结论

  • 联合免疫治疗与大分割放疗与历史队列相比未改善生存,放疗方案需优化以改善这些结果。

研究设计与样本

  • 多中心、非随机2期试验,2017年3月至2019年7月入组64例初治转移性黑色素瘤患者。
  • 患者接受纳武利尤单抗(240 mg/2周)联合放疗(第15天,6 Gy×3)。
  • 尽可能照射每个器官的一个靶病灶(不照射所有靶病灶)。
  • 主要终点为1年总生存(OS)。

主要发现

  • 中位随访23.5(2.3-43.8)个月,中位年龄68(35-95)岁,男性占67%,ECOG-PS 0分占72%,IV-M1c期占47%,BRAF野生型占67%。
  • 2年OS率和1年PFS率分别为65.2%和56%(P=0.22和P=0.03,对比Checkmate 066研究的58%和43%)。
  • 37例(58%)照射一个靶病灶,27例(42%)照射多个靶病灶。
  • ECOG-PS(1 vs 0;HR=3.5;P=0.005)是OS的独立预后因素。
  • 照射超过一个部位和照射较小累积肿瘤体积倾向于与更好结局相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiotherapy is thought to enhance anti-tumor immunity, particularly when delivered in a hypofractionated and multisite manner. Therefore, we investigated the effects of combining radiotherapy with nivolumab in patients with advanced melanoma. METHODS: This was a multicenter, non-randomized, phase 2 trial that enrolled patients with treatment-naïve metastatic melanoma. They received nivolumab (240 mg / 2 weeks) plus radiotherapy (day 15, 6 Gy × 3). When feasible, one target from each organ was irradiated (no irradiation of all targets). The primary endpoint was 1-year overall survival (OS). RESULTS: This trial included 64 patients between March 2017 and July 2019. The median follow-up was 23.5 (2.3-43.8) months. The median age was 68 (35-95) years, patients were mostly male (67 %) with an Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score of 0 (72 %), stage IV-M1c disease (47 %), and were BRAF-wild-type (67 %). The 2-year OS and 1-year PFS rates were 65.2 % and 56 %, respectively (P = 0.22 and P = 0.03, vs. 58 % and 43 %, respectively, in the Checkmate 066 study). Thirty-seven (58 %) and twenty-seven (42 %) patients were irradiated at one and multiple targets, respectively. The ECOG-PS (1 vs. 0; HR = 3.5; P = 0.005) was an independent prognostic factor for OS. Irradiating more than one site and irradiating a smaller cumulative tumor volume tended to correlate with better outcome. Grade 3-4 treatment-related adverse events occurred in 21.9 % of the patients (no grade 5). CONCLUSIONS: Combined immunotherapy and hypofractionated radiotherapy did not improve survival compared to historical cohorts. The radiotherapy schedule needs to be optimized in order to improve these results.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Doyen J, Dompmartin A, Cruzel C, et al. Nivolumab and hypofractionated radiotherapy in patients with advanced melanoma: A phase 2 trial. Eur J Cancer. 2025. PMID: 39864364. doi:10.1016/j.ejca.2025.115256

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。